Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label fampridine study in multiple sclerosis
2011-003507-38Phase 4Completed
- Sponsor
- Biogen
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalfampridine in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Change from baseline in SF-36 Physical Component Scale among responders. Started Oct 2011; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2011-003507-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003507-38.